Zentalis Pharmaceuticals Inc
ZNTL1.320USD
-0.120-8.33%
收盘 11/04, 16:00（美东）报价延迟15分钟
95.22M总市值
亏损市盈率 TTM
关于 Zentalis Pharmaceuticals Inc 公司
Zentalis Pharmaceuticals, Inc. 是一家临床阶段的生物制药公司。该公司专注于发现和开发针对癌症基本生物学途径的小分子疗法。该公司的主要候选产品包括 azenosertib (ZN-c3)，这是一种用于晚期实体瘤和血液系统恶性肿瘤的 WEE1 抑制剂。该公司还在开发一种用于治疗血液系统恶性肿瘤和相关疾病的 BCL-2 抑制剂 ZN-d5。ZN-d5 正在与 azenosertib 联合使用，在 R/R 急性髓系白血病 (AML) (ZN-d5-004C) 患者的 I/II 期剂量递增临床试验中进行评估。该公司还在利用其集成发现引擎推进对蛋白质降解剂和其他未公开靶标的研究。
Zentalis Pharmaceuticals Inc简介
公司代码ZNTL
公司名称Zentalis Pharmaceuticals Inc
上市日期Apr 03, 2020
CEOMs. Julie Eastland
员工数量166
证券类型Ordinary Share
年结日Apr 03
公司地址10275 Science Center Drive
城市SAN DIEGO
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编92121
电话18582634333
网址https://www.zentalis.com/
公司代码ZNTL
上市日期Apr 03, 2020
CEOMs. Julie Eastland
Zentalis Pharmaceuticals Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. David Michael Johnson
Mr. David Michael Johnson
Independent Director
Independent Director
250.42K
+29.87%
Dr. Jan Skvarka, Ph.D.
Dr. Jan Skvarka, Ph.D.
Independent Director
Independent Director
194.95K
+41.94%
Dr. Enoch Kariuki, Pharm.D.
Dr. Enoch Kariuki, Pharm.D.
Independent Director
Independent Director
137.37K
+72.22%
Dr. Ingmar Bruns, M.D.
Dr. Ingmar Bruns, M.D.
Chief Medical Officer
Chief Medical Officer
36.63K
--
Dr. Luke Walker, M.D.
Dr. Luke Walker, M.D.
Independent Director
Independent Director
--
--
Mr. Karan S. Takhar
Mr. Karan S. Takhar
Independent Director
Independent Director
--
--
Mr. Scott Myers
Mr. Scott Myers
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Julie Eastland
Ms. Julie Eastland
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. James B. Bucher, J.D.
Mr. James B. Bucher, J.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
名称
名称/职务
职务
持股
持股变动
Mr. David Michael Johnson
Mr. David Michael Johnson
Independent Director
Independent Director
250.42K
+29.87%
Dr. Jan Skvarka, Ph.D.
Dr. Jan Skvarka, Ph.D.
Independent Director
Independent Director
194.95K
+41.94%
Dr. Enoch Kariuki, Pharm.D.
Dr. Enoch Kariuki, Pharm.D.
Independent Director
Independent Director
137.37K
+72.22%
Dr. Ingmar Bruns, M.D.
Dr. Ingmar Bruns, M.D.
Chief Medical Officer
Chief Medical Officer
36.63K
--
Dr. Luke Walker, M.D.
Dr. Luke Walker, M.D.
Independent Director
Independent Director
--
--
Mr. Karan S. Takhar
Mr. Karan S. Takhar
Independent Director
Independent Director
--
--
收入明细
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2019
FY2018
暂无数据
地区USD
名称
营收
占比
United States
0.00
0.00%
业务
地区
暂无数据
股东统计
更新时间: 8月15日 周五
更新时间: 8月15日 周五
持股股东
股东类型
持股股东
持股股东
占比
Matrix Capital Management Company, LP
19.35%
Walters (William T)
9.77%
The Vanguard Group, Inc.
4.00%
Acadian Asset Management LLC
3.88%
Two Sigma Investments, LP
3.28%
其他
59.71%
持股股东
持股股东
占比
Matrix Capital Management Company, LP
19.35%
Walters (William T)
9.77%
The Vanguard Group, Inc.
4.00%
Acadian Asset Management LLC
3.88%
Two Sigma Investments, LP
3.28%
其他
59.71%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
29.24%
Hedge Fund
20.73%
Investment Advisor
13.86%
Individual Investor
12.70%
Research Firm
5.57%
Venture Capital
2.88%
Corporation
1.32%
Endowment Fund
0.24%
Family Office
0.12%
其他
13.33%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
354
52.36M
72.58%
-28.24M
2025Q2
374
67.79M
93.98%
-24.60M
2025Q1
386
70.02M
97.36%
-19.46M
2024Q4
379
71.39M
100.17%
-15.78M
2024Q3
373
74.19M
104.47%
-21.21M
2024Q2
365
79.92M
112.67%
-23.64M
2024Q1
360
88.75M
125.22%
-9.75M
2023Q4
361
83.47M
118.17%
-13.77M
2023Q3
361
82.76M
117.68%
-11.58M
2023Q2
361
84.96M
121.10%
+6.07M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Matrix Capital Management Company, LP
13.96M
19.35%
--
--
Jun 30, 2025
Walters (William T)
7.05M
9.77%
+3.05M
+76.25%
Jan 29, 2025
The Vanguard Group, Inc.
2.88M
4%
-375.98K
-11.53%
Jun 30, 2025
Acadian Asset Management LLC
2.80M
3.88%
+124.98K
+4.67%
Jun 30, 2025
Two Sigma Investments, LP
2.37M
3.28%
+977.03K
+70.19%
Jun 30, 2025
Opaleye Management Inc.
1.92M
2.67%
-60.70K
-3.06%
Jun 30, 2025
Almitas Capital LLC
1.60M
2.22%
-111.66K
-6.53%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.58M
2.2%
-2.25M
-58.69%
Jun 30, 2025
Tang Capital Management, LLC
1.55M
2.15%
+50.00K
+3.33%
Jun 30, 2025
Renaissance Technologies LLC
1.53M
2.12%
+703.51K
+85.17%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月2日 周日
更新时间: 11月2日 周日
机构名称
占比
Federated Hermes MDT Small Cap Core ETF
0.11%
iShares Micro-Cap ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Fidelity Enhanced Small Cap ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0%
Fidelity Fundamental Large Cap Growth ETF
0%
T Rowe Price Small-Mid Cap ETF
0%
Optimize Strategy Index ETF
0%
Humankind US Stock ETF
0%
Avantis US Equity ETF
0%
查看更多
Federated Hermes MDT Small Cap Core ETF
占比0.11%
iShares Micro-Cap ETF
占比0.02%
Invesco RAFI US 1500 Small-Mid ETF
占比0.01%
Fidelity Enhanced Small Cap ETF
占比0.01%
Invesco Nasdaq Biotechnology ETF
占比0%
Fidelity Fundamental Large Cap Growth ETF
占比0%
T Rowe Price Small-Mid Cap ETF
占比0%
Optimize Strategy Index ETF
占比0%
Humankind US Stock ETF
占比0%
Avantis US Equity ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
